Drug profile · INN
inotersen sodium
TEGSEDI
inotersen sodium (TEGSEDI) is a transthyretin mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — inotersen sodium
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 1
- Programs
- 2
- Data quality
- 0.84
Quick answer
inotersen sodium (TEGSEDI) is a transthyretin mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Transthyretin mRNA antisense inhibitor
Primary target: Transthyretin mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is inotersen sodium?
inotersen sodium (TEGSEDI) is a transthyretin mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for inotersen sodium?
TEGSEDI is a marketed brand name for inotersen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of inotersen sodium?
inotersen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.